Burger Menu

Orchestrating
innovation

Accelerating high-impact technologies to patients through risk reward sharing partnerships with leading medical device companies.
Our Approach

Our Approach

Our partnership enabled business model focuses on forging strategic collaborations with leading medical device companies to drive successful global commercialization of products we develop.

Our People

Our People

We are led by a highly accomplished, multidisciplinary management team and board of directors with extensive experience in all phases of therapeutic device development.

Our Pipeline

Our Pipeline

Our pipeline is comprised of innovative therapeutic product candidates that we believe have the potential for value creation using our partnership-enabled business model.

Our technologies

Our two late-stage flagship technologies are designed to address large unmet needs associated with the treatment of hypertension, a significant risk factor for death worldwide and atherosclerotic artery disease, the leading cause of mortality worldwide.
Atrioventricular Interval Modulation Therapy

Atrioventricular Interval Modulation Therapy

AVIM Therapy is an investigational patented bioelectronic treatment for hypertension that is designed to drive an immediate, substantial and sustained reduction in blood pressure while simultaneously modulating autonomic nervous system responses to maintain the reduction.

Learn more
Virtue® Sirolimus AngioInfusion™ Balloon (SAB)

Virtue® Sirolimus AngioInfusion™ Balloon (SAB)

Virtue SAB is an investigational patented drug/device combination product candidate for the treatment of artery disease designed to deliver a proprietary extended release formulation of sirolimus, Sirolimus EFR, during balloon angioplasty without the need for balloon coating or a permanent implant.

Learn more